Geron Corp (GERN) Dividend History

Company News

• GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm

  Geron Corporation (GERN) is facing a securities fraud lawsuit for allegedly making false and misleading statements about its drug Rytelo's launch and potential growth, leading to investor losses.

  Benzinga
• Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN

  Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation (GERN) for making false and/or misleading statements about its drug Rytelo. The company's stock price declined significantly after it announced that Rytelo's growth had flattened due to seasonality, competition, lack of awareness, and the burden of the monitoring requirement.

  GlobeNewswire Inc.
• Why Geron Stock Crept Higher Today

  Geron, a commercial-stage biotech company, reported its Q1 2023 results, which fell short of analyst expectations. While the company's cancer drug Rytelo generated $39.6 million in sales, it was lower than the $50.5 million analysts had projected. Geron maintained its guidance for operating expenses and cash runway.

  The Motley Fool
• Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up

  Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.

  Zacks Investment Research

  Featured Companies: ALXO BMY KRYS
• 3 'Buy-Rated' Biotech Stocks Under $10

  All three small-cap biotech/biopharma stocks have attractive risk/reward profiles and potential catalysts on the horizon. Click here for the complete stock list.

  Seeking Alpha

  Featured Companies: ADMA LYRA